Jamiruddin, Mohd. RaeedHasan, Amit2024-08-122024-08-12©20242024-02ID 18346085http://hdl.handle.net/10361/23720Cataloged from the PDF version of project report.Includes bibliographical references (pages 25-30).This project report is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.The treatment of colon cancer is a major healthcare issue that requires exploration of several treatment approaches. With an emphasis on overall survival, progression-free survival, and adverse events, this meta-analysis attempts to evaluate the efficacy and safety of TAS-102 and FOLFOX as a combination medication. The findings show that TAS-102 and FOLFOX both improve overall and progression-free survival, but that TAS-102 is more effective in the latter regard. There are significant variations in safety profiles between FOLFOX and TAS-102. TAS-102 shows better results, such as smaller confidence intervals and less severe side effects. The analyzed research indicates minimal publication bias. It is imperative to proceed with caution when generalizing these results to other demographic analysis.47 pagesenBrac University project reports are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.Cancer therapyTAS-102FOLFOXColon cancerProgression-free survivalTherapeutic synergyColon (Anatomy)--CancerCancer--TreatmentProject Report